

Timothy R Fouts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3558597/publications.pdf>

Version: 2024-02-01

45
papers

2,160
citations

257429

24
h-index

302107

39
g-index

46
all docs

46
docs citations

46
times ranked

2648
citing authors

#	ARTICLE	IF	CITATIONS
1	An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 9271-9276.	7.1	328
2	Epitope Mapping and Topology of Baculovirus-Expressed HIV-1 gp160 Determined with a Panel of Murine Monoclonal Antibodies. <i>AIDS Research and Human Retroviruses</i> , 1994, 10, 371-381.	1.1	179
3	NF- κ B-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer. <i>Cell Reports</i> , 2015, 11, 98-110.	6.4	178
4	Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E69-78.	7.1	138
5	Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 11842-11847.	7.1	117
6	Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E992-9.	7.1	117
7	Expression and Characterization of a Single-Chain Polypeptide Analogue of the Human Immunodeficiency Virus Type 1 gp120-CD4 Receptor Complex. <i>Journal of Virology</i> , 2000, 74, 11427-11436.	3.4	116
8	Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 17477-17482.	7.1	77
9	Cholera Toxin and Heat-Labile Enterotoxin Activate Human Monocyte-Derived Dendritic Cells and Dominantly Inhibit Cytokine Production through a Cyclic AMP-Dependent Pathway. <i>Infection and Immunity</i> , 2002, 70, 5533-5539.	2.2	75
10	Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 3952-3957.	7.1	70
11	Increased efficacy of HIV-1 neutralization by antibodies at low CCR5 surface concentration. <i>Biochemical and Biophysical Research Communications</i> , 2006, 348, 1107-1115.	2.1	62
12	Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. <i>Virology</i> , 2007, 363, 79-90.	2.4	57
13	Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach. <i>Journal of Controlled Release</i> , 2016, 244, 98-107.	9.9	57
14	Induction of Neutralizing Antibodies against Human Immunodeficiency Virus Type 1 Primary Isolates by Gag-Env Pseudovirion Immunization. <i>Journal of Virology</i> , 2005, 79, 14804-14814.	3.4	51
15	Gp120 stability on HIV-1 virions and Gag-Env pseudovirions is enhanced by an uncleaved Gag core. <i>Virology</i> , 2003, 314, 636-649.	2.4	47
16	Interactions of Polyclonal and Monoclonal Anti-Glycoprotein 120 Antibodies with Oligomeric Glycoprotein 120-Glycoprotein 41 Complexes of a Primary HIV Type 1 Isolate: Relationship to Neutralization. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 591-597.	1.1	46
17	Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 Region. <i>Structure</i> , 2016, 24, 697-709.	3.3	46
18	Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1. <i>Vaccine</i> , 2002, 20, 1968-1974.	3.8	37

#	ARTICLE	IF	CITATIONS
19	Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120. <i>Vaccine</i> , 1995, 13, 1697-1705.	3.8	36
20	Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. <i>Journal of Immunology</i> , 2016, 197, 2726-2737.	0.8	34
21	Optimization of live oral Salmonella-HIV-I vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses. <i>Journal of Biotechnology</i> , 1996, 44, 203-207.	3.8	31
22	Expression of Human Immunodeficiency Virus Type 1 Neutralizing Antibody Fragments Using Human Vaginal <i>Lactobacillus</i> . <i>AIDS Research and Human Retroviruses</i> , 2016, 32, 964-971.	1.1	31
23	Mucosal vaccine efficacy against intrarectal SHIV is independent of anti-Env antibody response. <i>Journal of Clinical Investigation</i> , 2019, 129, 1314-1328.	8.2	28
24	Structure and Function of the HIV Envelope Glycoprotein as Entry Mediator, Vaccine Immunogen, and Target for Inhibitors. <i>Advances in Pharmacology</i> , 2007, 55, 33-97.	2.0	27
25	Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1. <i>MAbs</i> , 2010, 2, 266-274.	5.2	21
26	HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques. <i>Virology</i> , 2014, 471-473, 81-92.	2.4	21
27	Conserved Structures Exposed in HIV-1 Envelope Glycoproteins Stabilized by Flexible Linkers as Potent Entry Inhibitors and Potential Immunogens. <i>Biochemistry</i> , 2002, 41, 7176-7182.	2.5	19
28	Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protection. <i>Molecular Systems Biology</i> , 2019, 15, e8747.	7.2	17
29	Identification and Characterization of an Immunogenic Hybrid Epitope Formed by both HIV gp120 and Human CD4 Proteins. <i>Journal of Virology</i> , 2011, 85, 13097-13104.	3.4	16
30	Antibody-based inhibitors of HIV infection. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 523-531.	3.1	14
31	An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model. <i>Viral Immunology</i> , 2017, 30, 178-195.	1.3	14
32	An Immunoglobulin Fusion Protein Based on the gp120-CD4 Receptor Complex Potently Inhibits Human Immunodeficiency Virus Type 1 in Vitro. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 477-490.	1.1	11
33	Adjuvant Activity of the Catalytic A1 Domain of Cholera Toxin for Retroviral Antigens Delivered by GeneGun. <i>Vaccine Journal</i> , 2011, 18, 922-930.	3.1	11
34	The catalytic A1 domains of cholera toxin and heat-labile enterotoxin are potent DNA adjuvants that evoke mixed Th1/Th17 cellular immune responses. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2228-2240.	3.3	9
35	Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques. <i>Journal of Virology</i> , 2020, 94, .	3.4	8
36	An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques. <i>Vaccine Journal</i> , 2016, 23, 618-627.	3.1	7

#	ARTICLE	IF	CITATIONS
37	Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial. <i>Vaccine</i> , 2021, 39, 3879-3891.	3.8	3
38	Neutralization of HIV by Antibodies. <i>Methods in Molecular Biology</i> , 2009, 525, 517-531.	0.9	2
39	Identification and Characterization of an Immunogenic Hybrid Epitope Formed by both HIV gp120 and Human CD4 Proteins. <i>Journal of Virology</i> , 2012, 86, 5410-5410.	3.4	1
40	P-C1â€fFull length single chain, a novel gp120-CD4 fusion HIV Subunit vaccine, does not cause a deleterious autoimmune CD4 response in cynomolgus macaques. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 89.	2.1	1
41	A-112â€fDNA and Protein Co-immunization Improves the Magnitude, Longevity, and mucosal dissemination of Immune Responses. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, 42.	2.1	0
42	G-111â€fDNA prime/subunit boost using SIVE660 based rhFLSC yields 75% efficacy against cross clade SIVmac251 intrarectal challenge. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 69.	2.1	0
43	P-B6â€fDevelopment of a Potency Assay for Full Length Single Chain, a subunit vaccine for HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 74.	2.1	0
44	F-106â€fTransition state Gp120 structures as HIV vaccines. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 71, 62.	2.1	0
45	Abstract 1836: Erlotinib induces NF-kappa B dependence that promotes EGFR tyrosine kinase inhibitor resistance in lung adenocarcinoma. , 2014, , .		0